Abnormal Results of Newborn Screening for SCID After Azathioprine Exposure In Utero: Benefit of TPMT Genotyping in Both Mother and Child

J Clin Immunol. 2022 Jan;42(1):199-202. doi: 10.1007/s10875-021-01138-9. Epub 2021 Oct 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azathioprine* / adverse effects
  • Child
  • Female
  • Genotype
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Infant, Newborn
  • Methyltransferases / genetics
  • Mothers
  • Neonatal Screening*

Substances

  • Immunosuppressive Agents
  • Methyltransferases
  • Azathioprine